Search clinical trials for: dalcetrapib (RO4607381)

Total 18 results

Hoffmann-La Roche

Completed

A Study of the Effect of RO4607381 on Atherosclerotic Plaque in Patients With Coronary Heart Disease

Coronary Heart Disease

United States, Canada
Hoffmann-La Roche

Completed

A Long Term Extension of Study NC19453 Evaluating Safety and Efficacy of RO4607381

Coronary Heart Disease

United States
Hoffmann-La Roche

Completed

A Study of RO4607381 in Stable Coronary Heart Disease Patients With Recent Acute Coronary Syndrome

Coronary Heart Disease

Belgium, Germany, Israel, Poland, Spain, United Kingdom, China, Korea, Republic of, United States, France, Switzerland, Canada, Ireland, New Zealand, South Africa, Hungary, Netherlands, Australia, Puerto Rico, Sweden, Austria, Arg... and more
Hoffmann-La Roche

Completed

A Study of RO4607381 in Patients With Coronary Heart Disease (CHD) or a CHD Risk Equivalent.

Coronary Heart Disease

Germany, United States
Hoffmann-La Roche

Completed

A Study Assessing the Effect of RO4607381 on Vascular Function in Patients With Coronary Heart Disease (CHD) or CHD-Risk Equivalent Patients

Coronary Heart Disease

Switzerland, France, Germany, Netherlands, Austria, Italy, United Kingdom
Hoffmann-La Roche

Completed

A Study of the Metabolic Profile of Dalcetrapib in Healthy Volunteers

Healthy Volunteer

Netherlands
Hoffmann-La Roche

Completed

A Study of Dalcetrapib in Patients With Stable Coronary Heart Disease, With Coronary Heart Disease Risk Equivalents or at Elevated Risk for Cardiovascular Disease

Cardiovascular Disease, Coronary Heart Disease, Dyslipidemia, Peripheral Arterial Disease (PAD)

China, United States, Spain, Netherlands, Canada, France, Mexico, Poland, Hungary, Australia, Denmark, United Kingdom, Czech Republic
Hoffmann-La Roche

Completed

A Study of Dalcetrapib in Patients Hospitalized For An Acute Coronary Syndrome (Dal-ACUTE)

Coronary Heart Disease

Netherlands, United States, United Kingdom, Czechia
DalCor Pharmaceuticals
Medpace, Inc.; The Montreal Health Innovations Coordinating Center (MHICC); Roche...

Completed

Effect of Dalcetrapib vs Placebo on CV Risk in a Genetically Defined Population With a Recent ACS (dal-GenE)

Acute Coronary Syndrome

Sweden, United States, Brazil, Bulgaria, France, Italy, Russian Federation, South Africa, Spain, Turkey, United Kingdom, Germany, Hungary, Poland, Romania, Canada, Argentina, Australia, Austria, Belgium, Chile, Czechia, Denmark, Finland, Isra... and more
DalCor Pharmaceuticals
The Montreal Health Innovations Coordinating Center (MHICC)

Recruiting

Effect of Dalcetrapib on CV Risk in a Genetically Defined Population With a Recent ACS (dal-GenE-2)

Acute Coronary Syndrome

United States, Canada, Puerto Rico
Hoffmann-La Roche

Completed

A Formulation Screening Study of Dalcetrapib and Atorvastatin in Healthy Volunteers

Healthy Volunteer

New Zealand
DalCor Pharmaceuticals
Covance; The Montreal Health Innovations Coordinating Center (MHICC)

Completed

Effect of Dalcetrapib in Patients With Confirmed Mild to Moderate COVID-19

Covid19

Canada
Hoffmann-La Roche

Terminated

A Study of the Effect of Dalcetrapib on Artherosclerotic Disease in Patients With Coronary Artery Disease

Cardiovascular Disease

Poland, United States, Switzerland, Canada, Germany
Hoffmann-La Roche

Completed

A Study to Assess the Effect of RO4607381 in Patients With Relatively Low Levels of High Density Lipoprotein-Cholesterol (HDL-C)

Dyslipidemia

United States
Japan Tobacco Inc.

Completed

Efficacy and Safety of JTT-705 300, 600 And 900mg in Comparison With Placebo in Patients With Type II Hyperlipidaemia

Type II Hyperlipidaemia

Netherlands
Akros Pharma Inc.

Completed

Safety and Efficacy Study of JTT-705 in Combination With Simvastatin 40 mg in Patients With Low High-Density Lipoprotein (HDL) Levels

Dyslipidemia

Netherlands
Akros Pharma Inc.

Completed

Safety and Efficacy Study of JTT-705 in Combination With Atorvastatin 20 mg in Patients With Low High-Density Lipoprotein (HDL) Levels

Dyslipidemia

Netherlands
Akros Pharma Inc.

Completed

Efficacy and Safety Study of JTT-705 in Combination With Pravastatin 40 mg in Patients With Type II Hyperlipidemia

Type II Hyperlipidemia

Netherlands

Search clinical trials for: dalcetrapib (RO4607381)

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Ecuador

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations